Clinical trials of the drug in Europe and the U.S. are making good progress
For treating Claudin18.2-positive advanced solid tumors.
LY03015 is used for the treatment of Tardive Dyskinesia and Huntington's Disease.
The results demonstrate LY03015’s high binding affinity for VMAT2 and excellent inhibition of DA uptake, indi...
For glycemic control in adult patients with type 2 diabetes.
TOP